Richard Kamm, MD
Pulmonary Disease · Shreveport, LANPI 1295835684
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,775 of the $8,330 with a category attached, or 69.3%. Actelion Pharmaceuticals US, Inc. accounts for 77.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $6,499 and has fallen 85.5% since, to $944 in 2025.
Across 80 payments — averaging $104.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$6K
- Intuitive Surgical$553
- Johnson & Johnson$310
- Abiomed$227
- Ceribell, Inc.$117
- Pfizer$95
- plus $609 from 18 others
Across 3 payments — averaging $2100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$6K
What the payments were for
- Speaking & faculty fees$5,77569%
- Travel & lodging$6488%
- Food & beverage$1,57219%
- Education$3354%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 21 | $6,419 |
| Intuitive Surgical | 2 | $553 |
| Johnson & Johnson(2 entities) | 15 | $310 |
| Abiomed | 3 | $227 |
| Ceribell, Inc. | 1 | $117 |
| Pfizer | 5 | $95 |
| Novo Nordisk | 2 | $93 |
| GSK | 4 | $71 |
| Portola Pharmaceuticals, LLC | 2 | $66 |
| AstraZeneca | 3 | $46 |
| Novartis | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $38 |
| Merck | 3 | $34 |
| Grifols USA, LLC | 1 | $24 |
| Boehringer Ingelheim | 2 | $23 |
| Medtronic | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Bayer | 1 | $19 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Insmed, Inc. | 1 | $16 |
| Biofire Diagnostics, LLC | 1 | $16 |
| La Jolla Pharmaceutical Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$5,899
- Da Vinci Surgical System$547
- POCKET EEG DEVICE$117
- Impella$102
How this compares
$8,330 in reported general payments places this provider in the 65th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Shreveport
- Robert HolladayShreveport$22K
- Scott HowardShreveport$20K
- David GreenShreveport$16K
- Himanshu DesaiShreveport$16K
- David ChambersShreveport$13K
- Ahmed ViraniShreveport$12K
- Ashley FerraroShreveport$10K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.